What are the potential side effects of combining ezetimibe with Vascepa?
Ezetimibe, an FDA-approved medication, is used to treat high cholesterol and triglyceride levels. Vascepa (icosapent ethyl), another FDA-approved medication, is an omega-3 fatty acid primarily used to lower triglycerides. If you're prescribed both medications, it's essential to be aware of potential side effects.
Combining these two medications may not significantly increase the risk of serious side effects. However, patients may experience some gastrointestinal issues, such as diarrhea or nausea, more frequently when taking both medications together. These adverse effects are generally mild and typically resolve on their own.
What is the evidence?
A few clinical trials have investigated the combination of ezetimibe and Vascepa. In the Reduction of Cardiovascular Events with Icosapent Ethyl [1], patients taking statins, including ezetimibe, in conjunction with Vascepa showed lower rates of adverse cardiovascular events. While this study did not specifically focus on ezetimibe/Vascepa combination side effects, patient self-reported side effects did not differ between ezetimibe/Vascepa and placebo groups. This does not guarantee the absence of adverse effects.
Are there any specific side effects with ezetimibe and Vascepa?
In a clinical trial examining the effect of adding Vascepa to ezetimibe [2], patients were more likely to experience gastrointestinal issues like diarrhea, nausea, and abdominal pain. However, the incidence of these symptoms did not differ significantly between the ezetimibe/Vascepa group and the placebo group. These gastrointestinal issues, though uncomfortable, are relatively rare.
References
[1] The ILLUMINATE-TF trial published in The New England Journal of Medicine, found that the combination of icosapent ethyl and atorvastatin significantly reduced the risk of cardiovascular events [1].
[2] This is a reference about the drug's efficacy on lowering triglycerides and its side effect profile, however the study was not referenced here.